Effets secondaires cutanés de l’association télaprévir/peg-interféron/ribavirine pour le traitement de l’hépatite C chronique : étude prospective d’une cohorte multicentrique

Lorcy, S.; Gaudy‐Marqueste, C.; Botta, D.; Portal, Isabelle; Quiles, N.; Oulies, V.; Mancini, Julien; Grob, Jean-Jacques; Richard, M.‐A.

doi:10.1016/j.annder.2016.02.028

Cited by 5 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ribavirin is used in combination with pegylated-interferon α2a (peg-IFN-α2a) for treating chronic hepatitis C, and both have been associated with several cutaneous DHRs (49). Ribavirin alone causes dermatitis, alopecia, and photoallergic eczematous reactions (50,51), and the risk of DHR increases with combination therapy: rash [response rate (RR,1.74; 95% confidence interval (CI), 1.17-2.6), dermatitis (RR, 1.67; 95% CI, 1.21-2.30), and pruritus (RR, 1.62; 95% CI,1.29-2.02) (52). A meta-analysis revealed that, on combination therapy, mild to moderate cutaneous reactions appear in 13.3% of patients, localized cutaneous reactions in 2.6%, generalized reactions-pruritus, skin xerosis and eczematous changes in 10.3%, alopecia in 4.1%, and exacerbation of lichen planus in less than 1% (43).…”

Section: Ribavirinmentioning

confidence: 99%

Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19

Gelincik

Brockow

Çelik

et al. 2020

Preprint

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19), a respiratory tract infection caused by a novel human coronavirus, the severe acute respiratory syndrome coronavirus 2, leads to a wide spectrum of clinical manifestations ranging from asymptomatic cases to patients with mild and severe symptoms, with or without pneumonia. Given the huge influence caused by the overwhelming COVID-19 pandemic affecting over three million people worldwide, a wide spectrum of drugs is considered for the treatment in the concept of repurposing and off-label use. There is no knowledge about the diagnosis and clinical management of the drug hypersensitivity reactions that can potentially occur during the disease. This review brings together all the published information about the diagnosis and management of drug hypersensitivity reactions due to current and candidate off-label drugs and highlights relevant recommendations. Furthermore, it gathers all the dermatologic manifestations reported during the disease for guiding the clinicians to establish a better differential diagnosis of drug hypersensitivity reactions in the course of the disease.

show abstract